BR9912356A - Regime de tratamento para a administração de fenilacetilglutamina, fenilacetilisoglutamina, e/ou fenilacetato - Google Patents
Regime de tratamento para a administração de fenilacetilglutamina, fenilacetilisoglutamina, e/ou fenilacetatoInfo
- Publication number
- BR9912356A BR9912356A BR9912356-8A BR9912356A BR9912356A BR 9912356 A BR9912356 A BR 9912356A BR 9912356 A BR9912356 A BR 9912356A BR 9912356 A BR9912356 A BR 9912356A
- Authority
- BR
- Brazil
- Prior art keywords
- phenylacetylisoglutamine
- phenylacetylglutamine
- phenylacetate
- pharmaceutical composition
- administration
- Prior art date
Links
- XBJLFHMAIQTBJX-JTQLQIEISA-N (4s)-5-amino-5-oxo-4-[(2-phenylacetyl)amino]pentanoic acid Chemical compound OC(=O)CC[C@@H](C(=O)N)NC(=O)CC1=CC=CC=C1 XBJLFHMAIQTBJX-JTQLQIEISA-N 0.000 title abstract 3
- JFLIEFSWGNOPJJ-JTQLQIEISA-N N(2)-phenylacetyl-L-glutamine Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)CC1=CC=CC=C1 JFLIEFSWGNOPJJ-JTQLQIEISA-N 0.000 title abstract 3
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 title abstract 2
- 229940049953 phenylacetate Drugs 0.000 title abstract 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 title abstract 2
- 238000011269 treatment regimen Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 5
- 238000000034 method Methods 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000007864 aqueous solution Substances 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000001802 infusion Methods 0.000 abstract 2
- 230000001613 neoplastic effect Effects 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Patente de Invenção: <B>"REGIME DE TRATAMENTO PARA A ADMINISTRAçãO DE FENILACETILGLUTAMINA, FENILACETILISOGLUTAMINA, E/OU FENILACETATO"<D>. Aqui é revelado um método de tratamento de doença neoplásica, incluindo câncer, compreendendo administração de uma composição farmacêutica, a composição farmacêutica compreendendo uma solução aquosa altamente concentrada de fenilacetilglutamina e fenilacetilisoglutamina em uma razão de 4:1, em uma taxa de infusão de desde 100 ml/hr a 400 ml/h. Em uma concretização ulterior, aqui é também revelado um método de tratamento de doença neoplásica, incluindo câncer, compreendendo administração de uma composição farmacêutica, a composição farmacêutica compreendendo uma solução aquosa altamente concentrada de fenilacetato e (fenilacetilglutamina ou fenilacetilisoglutamina) em uma razão de 4:1, em uma taxa de infusão de desde 100 ml/hr a 400 ml/hr. Aqui também são revelados as composições farmacêuticas usadas nos métodos acima.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/121,567 US6258849B1 (en) | 1998-07-23 | 1998-07-23 | Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate |
| PCT/US1999/015017 WO2000004894A2 (en) | 1998-07-23 | 1999-07-02 | Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9912356A true BR9912356A (pt) | 2001-04-17 |
Family
ID=22397538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9912356-8A BR9912356A (pt) | 1998-07-23 | 1999-07-02 | Regime de tratamento para a administração de fenilacetilglutamina, fenilacetilisoglutamina, e/ou fenilacetato |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US6258849B1 (pt) |
| EP (1) | EP1098643B1 (pt) |
| JP (2) | JP2002521329A (pt) |
| KR (4) | KR100417100B1 (pt) |
| CN (3) | CN100400039C (pt) |
| AT (1) | ATE257378T1 (pt) |
| AU (1) | AU759278B2 (pt) |
| BR (1) | BR9912356A (pt) |
| CA (1) | CA2336945C (pt) |
| DE (1) | DE69914084T2 (pt) |
| DK (1) | DK1098643T3 (pt) |
| EA (1) | EA004179B1 (pt) |
| ES (1) | ES2214866T3 (pt) |
| HK (1) | HK1037142A1 (pt) |
| ID (1) | ID28160A (pt) |
| IL (1) | IL140848A (pt) |
| NZ (1) | NZ509244A (pt) |
| PL (1) | PL213698B1 (pt) |
| PT (1) | PT1098643E (pt) |
| WO (1) | WO2000004894A2 (pt) |
| ZA (1) | ZA200100622B (pt) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6127419A (en) * | 1998-11-23 | 2000-10-03 | Burzynski; Stanislaw R. | Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis |
| ES2254470T3 (es) * | 2000-08-29 | 2006-06-16 | Nobex Corporation | Compuestos inmunorreguladores, derivados de los mismos y su uso. |
| US8048924B2 (en) | 2001-08-29 | 2011-11-01 | Biocon Limited | Methods and compositions employing 4-aminophenylacetic acid compounds |
| US7087219B2 (en) * | 2003-05-28 | 2006-08-08 | Stanislaw R. Burzynski | Toothpaste containing anticancer agents |
| US20060246016A1 (en) * | 2003-05-28 | 2006-11-02 | Burzynski Stanislaw R | Toothpaste containing anticancer agents |
| US7772108B2 (en) * | 2004-06-25 | 2010-08-10 | Samsung Electronics Co., Ltd. | Interconnection structures for semiconductor devices and methods of forming the same |
| PL1773767T3 (pl) | 2004-07-07 | 2016-07-29 | Biocon Ltd | Synteza azowo związanych związków immunoregulacyjnych |
| EP1786411A2 (en) * | 2004-07-28 | 2007-05-23 | Board of Regents, The University of Texas System | 3-halo-2-oxopropionate salts and esters as novel anticancer agents |
| ES2341120T3 (es) | 2004-11-26 | 2010-06-15 | Ucl Business Plc | Composiciones que comprenden ornitina y fenilacetato o fenilbutirato para tratar encefalopatia hepatica. |
| US20060205818A1 (en) * | 2005-03-08 | 2006-09-14 | Burzynski Stanislaw R | Method for the treatment of von Hippel-Lindau (VHL) disease with phenylacetyl-derivatives |
| CA2998344C (en) | 2009-04-03 | 2020-06-02 | Ocera Therapeutics, Inc. | L-ornithine phenyl acetate and methods of making thereof |
| MX2011013129A (es) | 2009-06-08 | 2012-03-14 | Ucl Business Plc | Tratamiento de hipertension portal y restauracion de la funcion hepatica usando fenilacetato de l-ornitina. |
| WO2012048043A1 (en) | 2010-10-06 | 2012-04-12 | Ocera Therapeutics, Inc. | Methods of making l-ornithine phenyl acetate |
| AU2015353703B2 (en) | 2014-11-24 | 2021-04-01 | Ucl Business Plc | Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies |
| JP6990170B2 (ja) | 2015-08-18 | 2022-01-12 | オセラ セラピューティクス， インコーポレイテッド | Ｌ－オルニチンをフェニルアセテートおよびフェニルブチレートのうちの少なくとも１つと組み合わせて用いる筋肉喪失の治療および予防 |
| WO2017114686A1 (en) * | 2015-12-30 | 2017-07-06 | Nestec S.A. | Method for determining fat free body mass |
| US10624869B2 (en) | 2017-05-08 | 2020-04-21 | Stanislaw R. Burzynski | Methods for the treatment of recurrent glioblastoma (RGBM) |
| JP7126520B2 (ja) | 2017-05-11 | 2022-08-26 | オセラ セラピューティクス， インコーポレイテッド | Ｌ－オルニチンフェニルアセテートを製造する方法 |
| MX2019014975A (es) * | 2017-06-12 | 2020-09-07 | Burzunski Res Institute Inc | Métodos para el tratamiento de la enfermedad leptomeningea. |
| US11344521B2 (en) | 2017-06-12 | 2022-05-31 | Burzynski Research Institute, Inc. | Methods for the treatment of leptomeningeal disease |
| CN116019798B (zh) * | 2022-07-20 | 2024-03-12 | 中南大学湘雅二医院 | 苯乙酰谷氨酰胺在制备预防和/或治疗阿霉素所致心脏毒性的药物中的应用 |
| CN116491472B (zh) * | 2022-12-14 | 2024-07-26 | 上海交通大学医学院附属第九人民医院 | 苯乙酰谷氨酰胺在构建慢性创面动物模型中的用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4284647A (en) | 1980-03-31 | 1981-08-18 | The Johns Hopkins University | Process for waste nitrogen removal |
| US4470970A (en) | 1981-07-02 | 1984-09-11 | Burzynski Stanislaw R | Purified antineoplaston fractions and methods of treating neoplastic disease |
| US5244922A (en) * | 1990-09-04 | 1993-09-14 | Burzynski Stanislaw R | Methods for treating viral infections |
| US5254587A (en) | 1990-09-04 | 1993-10-19 | Burzynski Stanislaw R | Methods for treating AIDS |
| US5605930A (en) | 1991-10-21 | 1997-02-25 | The United States Of America As Represented By The Department Of Health And Human Services | Compositions and methods for treating and preventing pathologies including cancer |
| US6013278A (en) | 1996-05-14 | 2000-01-11 | Burzynski Research Institute | Liposomal antineoplaston therapies with markedly improved antineoplastic activity |
-
1998
- 1998-07-23 US US09/121,567 patent/US6258849B1/en not_active Expired - Fee Related
-
1999
- 1999-07-02 AU AU48542/99A patent/AU759278B2/en not_active Ceased
- 1999-07-02 KR KR10-2003-7002799A patent/KR100417100B1/ko not_active IP Right Cessation
- 1999-07-02 IL IL14084899A patent/IL140848A/xx not_active IP Right Cessation
- 1999-07-02 KR KR10-2003-7002798A patent/KR100414587B1/ko not_active IP Right Cessation
- 1999-07-02 KR KR10-2001-7001021A patent/KR100399658B1/ko not_active IP Right Cessation
- 1999-07-02 BR BR9912356-8A patent/BR9912356A/pt not_active Application Discontinuation
- 1999-07-02 CA CA002336945A patent/CA2336945C/en not_active Expired - Fee Related
- 1999-07-02 DE DE69914084T patent/DE69914084T2/de not_active Expired - Lifetime
- 1999-07-02 PL PL345959A patent/PL213698B1/pl unknown
- 1999-07-02 JP JP2000560887A patent/JP2002521329A/ja active Pending
- 1999-07-02 KR KR10-2003-7002800A patent/KR100417101B1/ko not_active IP Right Cessation
- 1999-07-02 NZ NZ509244A patent/NZ509244A/xx not_active IP Right Cessation
- 1999-07-02 AT AT99932179T patent/ATE257378T1/de active
- 1999-07-02 WO PCT/US1999/015017 patent/WO2000004894A2/en active IP Right Grant
- 1999-07-02 CN CNB2004100616005A patent/CN100400039C/zh not_active Expired - Fee Related
- 1999-07-02 EA EA200100168A patent/EA004179B1/ru not_active IP Right Cessation
- 1999-07-02 PT PT99932179T patent/PT1098643E/pt unknown
- 1999-07-02 CN CNB99811314XA patent/CN1191064C/zh not_active Expired - Fee Related
- 1999-07-02 CN CNA2004100032827A patent/CN1605334A/zh active Pending
- 1999-07-02 EP EP99932179A patent/EP1098643B1/en not_active Expired - Lifetime
- 1999-07-02 ES ES99932179T patent/ES2214866T3/es not_active Expired - Lifetime
- 1999-07-02 ID IDW20010174A patent/ID28160A/id unknown
- 1999-07-02 DK DK99932179T patent/DK1098643T3/da active
-
2001
- 2001-01-22 ZA ZA2001/00622A patent/ZA200100622B/en unknown
- 2001-05-22 US US09/863,035 patent/US6943192B2/en not_active Expired - Lifetime
- 2001-11-09 HK HK01107897A patent/HK1037142A1/xx not_active IP Right Cessation
-
2010
- 2010-10-08 JP JP2010228241A patent/JP2011051993A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9912356A (pt) | Regime de tratamento para a administração de fenilacetilglutamina, fenilacetilisoglutamina, e/ou fenilacetato | |
| ES2162615T3 (es) | Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina. | |
| CY1111088T1 (el) | Θεραπευτικη φαρμακοτεχνικη μορφη για χορηγηση τολτεροδινης με ελεγχομενη απελευθερωση | |
| ES2137948T3 (es) | Sistema avanzado de administracion de medicamentos y metodo de tratamiento de trastornos psiquiatricos, neurologicos y otros con carbamacepina. | |
| HUP0300421A2 (hu) | Kezelési eljárás ligand-immunogén konjugátumok felhasználásával | |
| JO3404B1 (ar) | تركيبة صيدلانية سائلة تحتوي على مشتقات اريثروبويتين | |
| DE69713526D1 (de) | Lösliche prodrugs von paclitaxel | |
| ATE319447T1 (de) | Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen | |
| KR960704543A (ko) | 악성 질환의 치료를 위한 비경구투여용 부설판(Parenteral Busulfan for treatment of malignant disease) | |
| ATA21888A (de) | Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken | |
| BR9813318A (pt) | Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário | |
| KR970025615A (ko) | 암 전이 억제제 | |
| TR200002078T2 (tr) | Sentetik polisakkaridler, hazırlanmaları için proses ve bunları içeren farmasötik kompozisyonlar. | |
| KR910005858A (ko) | 지방산 요법 | |
| BR0212249A (pt) | Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto | |
| BR9406534A (pt) | Método para o tratamento de doença neoplástica utilizando tiazofurina e ribavirina | |
| HUP9903679A2 (hu) | Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására | |
| BR9611671A (pt) | Método de alvejamento de dosagens de medicamentos e de agentes terapêuticos e de outros glicosaminoglicanos (gags) para tratar de uma doença ou condição em um ser humano. | |
| AR005724A1 (es) | Derivados de ureido biologicamente activos utiles en el tratamiento de esclerosis multiple | |
| KR900017599A (ko) | 종양 치료용 약학 조성물 | |
| IT1229271B (it) | Preparazione medicinale di un estratto delle radici di ortica, urtica kiovensis (rogowicz), suo impiego per il trattamento di tumori e processo di preparazione. | |
| GEP20012377B (en) | Use of Trophoblastic Beta-1 Glycoprotein for Treating Auto-Immune Diseases and Method of Treatment These Diseases | |
| UA10301A (uk) | Спосіб лікуваhhя раку шлуhку | |
| RO102780B1 (ro) | Metoda de anestezie generala | |
| RO117893B1 (ro) | Metodă de anestezie generală, la cabaline |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE O MESMO NAO ATENDE AO DISPOSTO NOS ARTIGOS 8O, 11 E 13. |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |